The thing that stings most about this topic is how many women blame themselves — or let their partners silently blame them — for something that was happening in their bodies all along. If libido shifted around the same time everything else did, that is not a coincidence, and it is absolutely not a character flaw.
Learn more about Rose →While testosterone and estrogen do decline with age, that decline does not automatically sentence every woman to a permanently diminished sex life. Research consistently shows that many women who receive appropriate hormonal support — including low-dose testosterone or estrogen — report meaningful improvements in desire, arousal, and satisfaction. Calling it 'just aging' closes the door on a conversation that evidence says is absolutely worth having.
Testosterone is the primary hormone driving sexual desire in women, and levels fall by roughly 50% between a woman's twenties and her forties — well before the final menstrual period. This is a measurable physiological change, not a motivational failing. Framing low libido as a willpower problem causes real relational harm and prevents women from seeking physiological investigation.
Genitourinary syndrome of menopause (GSM) — which includes vaginal dryness, thinning of vaginal tissue, and reduced lubrication — affects up to 50% of postmenopausal women and makes intercourse genuinely, physically painful. Telling women to 'relax' ignores a documented physiological condition caused by estrogen withdrawal. Local estrogen therapy or non-hormonal vaginal moisturisers are evidence-backed treatments that directly address this.
Testosterone therapy for hypoactive sexual desire disorder (HSDD) in postmenopausal women has been studied in multiple randomised controlled trials and was the subject of a Global Consensus Position Statement co-signed by major endocrine and menopause societies in 2019. When used at physiological female doses — much lower than male doses — the safety profile is well-established in the short to medium term. The 'experimental' label is outdated and has been used to deny women a legitimate treatment option.
Oestrogen plays a significant role in genital tissue health, clitoral sensitivity, and vaginal lubrication — all of which support sexual response. Restoring systemic or local oestrogen levels through hormone therapy can meaningfully improve these functions, and evidence supports improvements in arousal and orgasm as well as comfort. The idea that the sexual response system is permanently switched off by menopause is not supported by physiology or clinical data.
Relationship quality does influence desire — that part is true — but attributing all menopausal low libido to partnership problems is both reductive and harmful. Studies using validated tools to assess HSDD in menopausal women consistently find that hormonal changes are a primary driver independent of relationship satisfaction. Sending women to couples counselling without first investigating their hormonal picture is putting the cart well before the horse.
SSRIs and SNRIs are sometimes prescribed during perimenopause for mood symptoms, hot flushes, or both — and they can genuinely help with those things. However, sexual dysfunction including reduced desire, delayed orgasm, and reduced genital sensation is among the most common side effects of this drug class, affecting anywhere from 30% to 70% of users depending on the study. Women deserve to know this trade-off explicitly before they start, not after they notice the change.
Large population studies, including the National Survey of Sexual Health and Behavior, consistently show that many women remain sexually active and interested well into their sixties and seventies. The idea that wanting a satisfying sex life past fifty is somehow striving against nature reflects a cultural bias, not a biological fact. This myth causes women to feel embarrassed about seeking help and discourages clinicians from taking their concerns seriously.
While it is true that not all clinicians are equally trained in menopause medicine, the landscape is changing — and there are now recognised pathways including menopause specialists, sexual health clinics, and trained psychosexual therapists who can offer real, evidence-based support. Conditions like HSDD have formal diagnostic criteria and approved or off-label treatment options that a well-informed clinician can discuss. Giving up before asking means potentially leaving years of treatable symptoms on the table.
Rose covers every symptom, supplement, and condition in full detail — evidence-graded and agenda-free.
Rose is a free, evidence-based reference built for women navigating perimenopause and menopause. No ads. No products to sell. No agenda. Just honest answers — because every woman in this season deserves a trusted friend who has done the research.